Una vacuna experimental de ARNm muestra protección contra múltiples virus del Ébola

22 de mayo de 2026

Reportado por IA

Una vacuna experimental de ARNm ha demostrado eficacia contra tres cepas del virus del Ébola en pruebas con roedores. La vacuna se dirige a los virus Zaire, Sudán y Bundibugyo. Los investigadores la desarrollaron en medio de un brote continuo del virus Bundibugyo en África.

Yanfeng Yao y sus colegas del Instituto de Virología de Wuhan crearon la vacuna combinando secuencias de ARNm para las glicoproteínas de cada virus junto con una nucleoproteína compartida dentro de una nanopartícula lipídica. En las pruebas, los ratones inmunizados obtuvieron protección completa contra los virus Zaire y Sudán, y una fuerte protección contra el Bundibugyo. Los hámsteres también recibieron protección total tras la exposición al virus Sudán.

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

5 de junio de 2026 Reportado por IA Imagen generada por IA Verificado por hechos

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Engineered phages redirect vaccine immunity to eradicate tumors in mice

Researchers have used genetically modified phages to harness pre-existing vaccine immunity and destroy cancer cells in mice. The approach eradicated tumors in 44 percent of treated animals with no recurrence after a year.

Moderna advances hantavirus vaccine after cruise ship deaths

11 de mayo de 2026 Reportado por IA

Moderna confirmed ongoing work on an mRNA vaccine for hantavirus following a deadly outbreak on a Dutch cruise ship. The effort, in partnership with Korea University, began in 2023 and shows promise but remains years from completion.

Asia

Philippines remains free of Ebola, DOH says

Africa

Scientists warn of bat coronavirus risk in East Africa

Africa

WHO warns of Ebola spread risk as Kenya activates emergency response measures

Virus injection halts pancreatic tumor growth in trial

A genetically engineered virus has stopped pancreatic tumors from growing in three patients in an early US clinical trial. The results come from a safety study led by researchers at the University of Minnesota.

Scripps researchers reveal HIV and Ebola weak spots using nanodiscs

12 de abril de 2026 Reportado por IA

Scientists at Scripps Research have developed a nanodisc platform that mimics viral membranes, uncovering hidden interactions in HIV and Ebola proteins that traditional methods miss. The technology allows for more accurate study of antibody responses, potentially accelerating vaccine development. The findings appear in Nature Communications.

13 de junio de 2026 13:47